JP2019500894A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500894A5
JP2019500894A5 JP2018543279A JP2018543279A JP2019500894A5 JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5 JP 2018543279 A JP2018543279 A JP 2018543279A JP 2018543279 A JP2018543279 A JP 2018543279A JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5
Authority
JP
Japan
Prior art keywords
amino acid
variant
seq
domain
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543279A
Other languages
English (en)
Japanese (ja)
Other versions
JP6932709B2 (ja
JP2019500894A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/060724 external-priority patent/WO2017079694A2/en
Publication of JP2019500894A publication Critical patent/JP2019500894A/ja
Publication of JP2019500894A5 publication Critical patent/JP2019500894A5/ja
Priority to JP2021133074A priority Critical patent/JP7264954B2/ja
Application granted granted Critical
Publication of JP6932709B2 publication Critical patent/JP6932709B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543279A 2015-11-04 2016-11-04 Her2を標的とするキメラ抗原受容体 Expired - Fee Related JP6932709B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021133074A JP7264954B2 (ja) 2015-11-04 2021-08-18 Her2を標的とするキメラ抗原受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562251052P 2015-11-04 2015-11-04
US62/251,052 2015-11-04
PCT/US2016/060724 WO2017079694A2 (en) 2015-11-04 2016-11-04 Chimeric antigen receptors targeting her2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021133074A Division JP7264954B2 (ja) 2015-11-04 2021-08-18 Her2を標的とするキメラ抗原受容体

Publications (3)

Publication Number Publication Date
JP2019500894A JP2019500894A (ja) 2019-01-17
JP2019500894A5 true JP2019500894A5 (enExample) 2019-12-19
JP6932709B2 JP6932709B2 (ja) 2021-09-08

Family

ID=58662864

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543279A Expired - Fee Related JP6932709B2 (ja) 2015-11-04 2016-11-04 Her2を標的とするキメラ抗原受容体
JP2021133074A Active JP7264954B2 (ja) 2015-11-04 2021-08-18 Her2を標的とするキメラ抗原受容体
JP2023065384A Withdrawn JP2023100653A (ja) 2015-11-04 2023-04-13 Her2を標的とするキメラ抗原受容体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021133074A Active JP7264954B2 (ja) 2015-11-04 2021-08-18 Her2を標的とするキメラ抗原受容体
JP2023065384A Withdrawn JP2023100653A (ja) 2015-11-04 2023-04-13 Her2を標的とするキメラ抗原受容体

Country Status (13)

Country Link
US (3) US11197919B2 (enExample)
EP (2) EP3371227B8 (enExample)
JP (3) JP6932709B2 (enExample)
KR (1) KR20180083874A (enExample)
CN (2) CN108779174B (enExample)
AU (2) AU2016349722A1 (enExample)
BR (1) BR112018009129A2 (enExample)
CA (1) CA3004306A1 (enExample)
ES (1) ES2909973T3 (enExample)
IL (2) IL259120B (enExample)
MX (2) MX2018005674A (enExample)
RU (1) RU2753695C2 (enExample)
WO (1) WO2017079694A2 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
BR112018009129A2 (pt) * 2015-11-04 2019-02-26 J. PRICEMAN Saul receptores de antígeno quimérico que visam her2
IL287889B2 (en) 2016-02-05 2024-03-01 Hope City Administration of engineered t cells for treatment of cancers in the central nervous system
US20200095547A1 (en) * 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
EP3567049A4 (en) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
JP2020506971A (ja) 2017-02-08 2020-03-05 ドラゴンフライ セラピューティクス, インコーポレイテッド ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US12116417B2 (en) 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN109608547B (zh) * 2017-12-29 2022-03-15 郑州大学第一附属医院 表达Her2的嵌合抗原受体、慢病毒表达载体及其应用
FI3749346T3 (fi) 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
CN111712516A (zh) * 2018-02-09 2020-09-25 新加坡国立大学 粘附受体构建体及其在自然杀伤细胞免疫疗法中的用途
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
AU2019216989B2 (en) * 2018-02-11 2025-08-28 The Regents Of The University Of California CAR-T cells and autoimmune diseases
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
MX2020008684A (es) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
WO2019222579A1 (en) * 2018-05-17 2019-11-21 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors with myd88 and cd40 costimulatory domains
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16及び腫瘍関連抗原に結合するタンパク質
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
US20230065784A1 (en) 2019-03-21 2023-03-02 City Of Hope Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
CA3139319A1 (en) * 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of polypeptides and chimeric antigen receptors via hinge domains
WO2021151119A1 (en) * 2020-01-23 2021-07-29 Exuma Biotech Corp. Chimeric antigen receptors to her2 and methods of use thereof
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合nkg2d、cd16及clec12a之蛋白質
WO2021235894A1 (en) * 2020-05-22 2021-11-25 Green Cross Lab Cell Corporation Anti-HER2 Antibody or Antigen-binding Fragment thereof, and Chimeric Antigen Receptor Comprising Same
CN112481284B (zh) * 2020-12-07 2023-07-25 深圳瑞吉生物科技有限公司 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用
WO2022187182A1 (en) * 2021-03-02 2022-09-09 The Trustees Of The University Of Pennsylvania Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
US20240366662A1 (en) 2021-03-30 2024-11-07 City Of Hope Car t cell therapy and ifn gamma
WO2023274385A1 (zh) * 2021-07-01 2023-01-05 宁波茂行生物医药科技有限公司 靶向her2的通用型car-t细胞及其制备方法
JP2024528038A (ja) 2021-07-29 2024-07-26 ソノマ バイオセラピューティクス, インコーポレイテッド 調節性t細胞を標的として自己免疫疾患を処置するための滑膜細胞外マトリックス特異的キメラ抗原受容体
JP2024531475A (ja) * 2021-08-24 2024-08-29 賽斯尓▲チン▼生物技術(上海)有限公司 T細胞製品およびその使用
CN116023491A (zh) 2021-10-25 2023-04-28 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其应用
WO2023172514A1 (en) * 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
JP2025508102A (ja) 2022-03-10 2025-03-21 シティ・オブ・ホープ 細胞性免疫療法のための膜結合型il-12
IL316101A (en) 2022-04-08 2024-12-01 Fate Therapeutics Inc Skeletal cells refer to solid tumors and their use
KR20250004622A (ko) * 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
CN114805584B (zh) * 2022-06-30 2022-09-09 上海优替济生生物医药有限公司 抗原结合蛋白及其用途
AU2024264153A1 (en) 2023-04-27 2025-11-13 Vanudis GmbH Coreceptor chimeric antigen receptor
US20250146017A1 (en) 2023-11-06 2025-05-08 City Of Hope Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
CN117924518B (zh) * 2024-01-05 2025-08-22 苏州艾凯利元生物科技有限公司 用于nk细胞的嵌合抗原受体及工程化的nk细胞
WO2025184170A1 (en) 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540856B2 (ja) * 1999-04-09 2010-09-08 ウニヴェルジテート・チューリッヒ キメラ免疫グロブリンまたは免疫グロブリン断片の新規安定化方法、および安定化された抗EGP−2scFv断片
KR20190126461A (ko) 2004-07-22 2019-11-11 제넨테크, 인크. Her2 항체 조성물
WO2008143954A2 (en) * 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
HRP20190556T1 (hr) 2009-11-03 2019-06-14 City Of Hope SKRAĆENI OBLIK RECEPTORA EPIDERMALNOG FAKTORA RASTA ZA (EGFRt) ODABIR TRANSDUCIRANIH T-STANICA
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
US8491908B2 (en) * 2010-06-01 2013-07-23 Canon Kabushiki Kaisha Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle
WO2012050374A2 (en) * 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
MX359513B (es) * 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
RU2616881C2 (ru) * 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
IL293944A (en) * 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
JP6306596B2 (ja) * 2012-10-04 2018-04-04 リサーチ ディベロップメント ファウンデーション セリンプロテアーゼ分子および療法
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
IL238323B2 (en) * 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
DK3039040T3 (da) * 2013-08-26 2022-02-07 Hinrich Abken Kimær anti cd30-antigenreceptor og anvendelse deraf
CN107074957B (zh) * 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
JP2017514471A (ja) * 2014-04-23 2017-06-08 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム キメラ抗原受容体(car)並びにその製造及び使用方法
BR112018009129A2 (pt) * 2015-11-04 2019-02-26 J. PRICEMAN Saul receptores de antígeno quimérico que visam her2

Similar Documents

Publication Publication Date Title
JP2019500894A5 (enExample)
RU2018118817A (ru) Химерные рецепторы антигена, нацеленные на her2
JP7527049B2 (ja) Car発現ベクター及びcar発現t細胞
IL292650A (en) Chimeric antigen receptor T cells target il13ra2
TWI710572B (zh) 改善配對的t細胞受體
JP2017537627A5 (enExample)
ES2833162T3 (es) Receptor de antígeno quimérico y su uso
RU2018113510A (ru) Химерные рецепторы антигена, нацеленные на psca
RU2685479C2 (ru) Химерный антигенный рецептор
CN104177499B (zh) 一种嵌合抗原受体、编码基因、表达载体及其应用
RU2017121826A (ru) Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1
ES2959480T3 (es) Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
ES2848478T3 (es) Receptores quiméricos para antígenos y usos de estos
JP2015518479A5 (enExample)
JP2017500869A5 (enExample)
JP2019528078A (ja) 細胞治療のための構造的に活性なサイトカイン受容体
RU2016143384A (ru) Трансгенные генетические метки и способы применения
JP2016520074A5 (enExample)
JP2018509163A5 (enExample)
JP2016538855A5 (enExample)
CN108779160A (zh) 施用工程化t细胞以治疗中枢神经系统中的癌症
JP2017538401A5 (enExample)
JPWO2020014366A5 (enExample)
Wang et al. Minicircle DNA-mediated CAR T cells targeting CD44 suppressed hepatocellular carcinoma both in vitro and in vivo
JP2019512251A5 (enExample)